BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma

Sara Busacca1, Michael Sheaff, Kenneth Arthur

  • 1Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK.

The Journal of Pathology
|December 23, 2011
PubMed

Insights

BRCA1 is essential for vinorelbine to induce apoptosis in malignant pleural mesothelioma (MPM). Loss of BRCA1 expression in 38.9% of MPM samples suggests its potential as a predictive biomarker for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant pleural mesothelioma (MPM) has limited therapeutic options.
  • Vinorelbine shows activity, but biomarkers for treatment optimization are lacking.
  • The role of BRCA1 in vinorelbine-induced apoptosis in MPM is unknown.

Purpose of the Study:

  • To investigate the role of BRCA1 in vinorelbine-induced apoptosis in MPM.
  • To evaluate BRCA1 as a potential predictive biomarker for vinorelbine therapy in MPM.

Main Methods:

  • Correlation analysis of vinorelbine sensitivity and BRCA1 expression.
  • siRNA-mediated BRCA1 knockdown to induce vinorelbine resistance.
  • Assessment of BRCA1 expression in 144 primary MPM specimens via immunohistochemistry.

Main Results:

  • Vinorelbine sensitivity strongly correlated with BRCA1 expression levels.
  • BRCA1 knockdown induced resistance to vinorelbine.
  • BRCA1 expression was significantly down-regulated in vinorelbine-resistant cells.
  • BRCA1 re-expression restored vinorelbine-induced apoptosis.
  • Loss of BRCA1 protein expression was observed in 38.9% of MPM samples.

Conclusions:

  • BRCA1 plays a critical role in mediating vinorelbine-induced apoptosis in MPM.
  • BRCA1 is a potential predictive biomarker for vinorelbine treatment in MPM.
  • Clinical evaluation of BRCA1 as a biomarker is warranted.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...